Drug × Cancer matrix

Each row is a drug, each column a cancer subtype. Cells show the strongest known association for that drug in that cancer: approved clinical trial or blank. The repositionable flag means the drug appears as a synthetic-lethal repositioning candidate in cansar; it’s gene-level, not cancer-level.

Cancer key
GBM — Glioblastoma (CNS astrocytoma grade IV) LUAD — Lung adenocarcinoma SCLC — Small cell lung carcinoma LUSC — Lung squamous cell carcinoma OAC — Oesophageal adenocarcinoma OSCC — Oesophageal squamous cell carcinoma PDAC — Pancreatic ductal adenocarcinoma
Clear
Showing 13 of 13 matching drugs for NRG1 — including drugs targeting any of its 162 synthetic-lethal partners , sorted by total cancer coverage.
Drug Target Relationship GBM LUAD SCLC LUSC OAC OSCC PDAC Reposition #cancers
biospecimen collection, computed tomography, devimistat, fluorouracil, gemcitabine hydrochloride, hydroxychloroquine, magnetic resonance imaging ACE2 SSL via ACE2 2
3-dimensional conformal radiation therapy, intensity-modulated radiation therapy (imrt), temozolomide, chloroquine, tumor treating fields therapy (ttf) ACE2 SSL via ACE2 1
binimetinib, hydroxychloroquine ACE2 SSL via ACE2 1
chloroquine ACE2 SSL via ACE2 1
chloroquine, radiotherapy, temozolomide ACE2 SSL via ACE2 1
cobimetinib, hydroxychloroquine, atezolizumab ACE2 SSL via ACE2 1
gemcitabine, abraxane, hydroxychloroquine ACE2 SSL via ACE2 1
gemcitabine, hydroxychloroquine, nab-paclitaxel, paricalcitol ACE2 SSL via ACE2 1
hydroxychloroquine, gemcitabine ACE2 SSL via ACE2 1
hydroxychloroquine, radiotherapy ACE2 SSL via ACE2 1
hydroxychloroquine, temozolomide, pharmacological study, radiation ACE2 SSL via ACE2 1
paclitaxel protein bound, gemcitabine, cisplatin, hydroxychloroquine ACE2 SSL via ACE2 1
paricalcitol, hydroxychloroquine, losartan, neoadjuvant therapy and surgery only (control) ACE2 SSL via ACE2 1
Approval data manually curated from National Cancer Institute and Drugs@FDA. Clinical trials from ClinicalTrials.gov. Repositionable list from cansar.ai.